Nom du produit:2-(2-bromo-5-methoxyphenyl)-1,3-dioxolane

IUPAC Name:2-(2-bromo-5-methoxyphenyl)-1,3-dioxolane

CAS:98015-07-7
Formule moléculaire:C10H11BrO3
Pureté:95%
Numéro de catalogue:CM279844
Poids moléculaire:259.1

Unité d'emballage Stock disponible Prix($) Quantité
CM279844-1g in stock ŁŁǎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:98015-07-7
Formule moléculaire:C10H11BrO3
Point de fusion:-
Code SMILES:COC1=CC=C(Br)C(C2OCCO2)=C1
Densité:
Numéro de catalogue:CM279844
Poids moléculaire:259.1
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Dioxolanes
Dioxolane is a heterocyclic acetal with the formula (CH2)2O2CH2. It is related to tetrahydrofuran by exchanging an oxygen for the CH2 group. The isomer 1,2-dioxolane (in which the two oxygen centers are adjacent) is a peroxide. 1,3-Dioxolane is used as solvent and comonomer in polyacetal. The dioxolane-type and their hydrogenolysis can provide very valuable partially protected building blocks either for oligosaccharide syntheses or sugar transformations.

Column Infos

Sparsentan
CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria. 

Related Products